Waldenström’s Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013

Restricted access

These NCCN Guidelines Insights highlight the important updates/changes specific to the management of Waldenström’s Macroglobulinemia/Lymphoplasmacytic Lymphoma. These include the addition of regimens containing novel agents as primary and salvage therapy options, inclusion of the updated summary of response categories and criteria from the sixth international workshop on Waldenström’s Macroglobulinemia, and a section on management of peripheral neuropathy in the accompanying discussion.

  • 1

    OwenRGTreonSPAl-KatibA. Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol2003;30:110115.

    • Search Google Scholar
    • Export Citation
  • 2

    HarrisNLJaffeESDieboldJ. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol1999;17:38353849.

    • Search Google Scholar
    • Export Citation
  • 3

    SwerdlowSHBergerFPileriSA. Lymphoplasmacytic lymphoma. In: SwerdlowSHCampoEHarrisNL. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues4th ed.Lyon, France: IARC Press; 2008:194.

    • Search Google Scholar
    • Export Citation
  • 4

    SekharJSanfilippoKZhangQ. Waldenstrom macroglobulinemia: a Surveillance, Epidemiology, and End Results database review from 1988 to 2005. Leuk Lymphoma2012;53:16251626.

    • Search Google Scholar
    • Export Citation
  • 5

    FonsecaRHaymanS. Waldenstrom macroglobulinaemia. Br J Haematol2007;138:700720.

  • 6

    KyleRATreonSPAlexanianR. Prognostic markers and criteria to initiate therapy in Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol2003;30:116120.

    • Search Google Scholar
    • Export Citation
  • 7

    TreonSP. How I treat Waldenstrom macroglobulinemia. Blood2009;114:23752385.

  • 8

    ChenCIKouroukisCTWhiteD. Bortezomib is active in patients with untreated or relapsed Waldenstrom’s macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol2007;25:15701575.

    • Search Google Scholar
    • Export Citation
  • 9

    GhobrialIMXieWPadmanabhanS. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom macroglobulinemia. Am J Hematol2010;85:670674.

    • Search Google Scholar
    • Export Citation
  • 10

    TreonSPIoakimidisLSoumeraiJD. Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol2009;27:38303835.

    • Search Google Scholar
    • Export Citation
  • 11

    ChenCKouroukisCTWhiteD. Bortezomib in relapsed or refractory Waldenstrom’s macroglobulinemia. Clin Lymphoma Myeloma2009;9:7476.

  • 12

    RummelMJvon GruenhagenUNiederleN. Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with Waldenstrom’s macroglobulinemia: first interim results of a randomized phase III study of the Study Group Indolent Lymphomas (StiL) [abstract]. Presented at the 5th International Workshop on Waldenstrom’s macroglobulinemia; October 15–18, 2008; Stockholm, Sweden. Abstract 139.

    • Search Google Scholar
    • Export Citation
  • 13

    TreonSPHanzisCAIoakimidisLI. Clinical characteristics and treatment outcome of disease-related peripheral neuropathy in Waldenstrom’s macroglobulinemia (WM) [abstract]. J Clin Oncol2010;28(15 Suppl):Abstract 8114.

    • Search Google Scholar
    • Export Citation
  • 14

    BenedettiLBrianiCGrandisM. Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M. J Peripher Nerv Syst2007;12:102107.

    • Search Google Scholar
    • Export Citation
  • 15

    DalakasMCRakocevicGSalajeghehM. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol2009;65:286293.

    • Search Google Scholar
    • Export Citation
  • 16

    PestronkAFlorenceJMillerT. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry2003;74:485489.

    • Search Google Scholar
    • Export Citation
  • 17

    TreonSPGertzMADimopoulosM. Update on treatment recommendations from the Third International Workshop on Waldenstrom’s macroglobulinemia. Blood2006;107:34423446.

    • Search Google Scholar
    • Export Citation
  • 18

    DimopoulosMAGertzMAKastritisE. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom’s Macroglobulinemia. J Clin Oncol2009;27:120126.

    • Search Google Scholar
    • Export Citation
  • 19

    GhobrialIMFonsecaRGreippPR. Initial immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer2004;101:25932598.

    • Search Google Scholar
    • Export Citation
  • 20

    TreonSPBranaganARHunterZ. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom’s macroglobulinemia. Ann Oncol2004;15:14811483.

    • Search Google Scholar
    • Export Citation
  • 21

    TreonSPHunterZRMatousJ. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom’s macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res2007;13:33203325.

    • Search Google Scholar
    • Export Citation
  • 22

    StraussSJMaharajLHoareS. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol2006;24:21052112.

    • Search Google Scholar
    • Export Citation
  • 23

    TreonSTripsasCIoakimidisL. Prospective, multicenter study of the mTOR inhibitor everolimus (RAD001) as primary therapy in Waldenstrom’s macroglobulinemia [abstract]. Presented at the 53rd ASH Annual Meeting and Exposition; December 10–13, 2011; San Diego, California. Abstract 2951.

    • Search Google Scholar
    • Export Citation
  • 24

    VargheseAMRawstronACAshcroftAJ. Assessment of bone marrow response in Waldenstrom’s macroglobulinemia. Clin Lymphoma Myeloma2009;9:5355.

    • Search Google Scholar
    • Export Citation
  • 25

    TreonSPMerliniGMorraE. Report from the Sixth International Workshop on Waldenstrom’s Macroglobulinemia. Clin Lymphoma Myeloma Leuk2011;11:6873.

    • Search Google Scholar
    • Export Citation
  • 26

    AgathocleousARohatinerARuleS. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstrom macroglobulinaemia. Br J Haematol2010;151:346353.

    • Search Google Scholar
    • Export Citation
  • 27

    GhobrialIMMatousJPadmanabhanS. Phase II trial of combination of bortezomib and rituximab in relapsed and/or refractory Waldenstrom macroglobulinemia [abstract]. J Clin Oncol2009;27(15 Suppl):Abstract 8535.

    • Search Google Scholar
    • Export Citation
  • 28

    DimopoulosMAAnagnostopoulosAKyrtsonisMC. Treatment of relapsed or refractory Waldenstrom’s macroglobulinemia with bortezomib. Haematologica2005;90:16551658.

    • Search Google Scholar
    • Export Citation
  • 29

    GhobrialIMHongFPadmanabhanS. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol2010;28:14221428.

    • Search Google Scholar
    • Export Citation
  • 30

    TreonSPHanzisCTripsasC. Bendamustine therapy in patients with relapsed or refractory Waldenstrom’s macroglobulinemia. Clin Lymphoma Myeloma Leuk2011;11:133135.

    • Search Google Scholar
    • Export Citation
  • 31

    GhobrialIMGertzMALaPlantB. A phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory waldenstrom’s macroglobulinemia [abstract]. Blood2009;114:Abstract 587.

    • Search Google Scholar
    • Export Citation
  • 32

    FurmanRREradatHSwitzkyJC. A phase II trial of ofatumumab in subjects with Waldenstrom’s macroglobulinemia [abstract]. Blood2010;116:Abstract 1795.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 271 271 42
PDF Downloads 82 82 9
EPUB Downloads 0 0 0